You have free access to this content

Cancer

Cover image for Cancer

1 May 1998

Volume 82, Issue 9

Pages 1609–1802

  1. Cancer—50 Years Later

    1. Top of page
    2. Cancer—50 Years Later
    3. Editorials
    4. Original Articles
    5. Correspondence
    6. Errata
    1. You have free access to this content
      Total pelvic exenteration (pages 1609–1610)

      Hugh R. K. Barber

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1609::AID-CNCR1>3.0.CO;2-5

      Fifty years ago Dr. Alexander Brunschwig described a radical surgical procedure for the treatment of patients with advanced pelvic carcinoma, offering these women a second chance for survival. Although modifications have been made to the procedure since Dr. Brunschwig's initial report, it remains a landmark contribution to the management of this disease.

  2. Editorials

    1. Top of page
    2. Cancer—50 Years Later
    3. Editorials
    4. Original Articles
    5. Correspondence
    6. Errata
    1. You have free access to this content
      Revision of TNM classification for oral pharyngeal carcinoma (pages 1611–1612)

      Irvin D. Fleming

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1611::AID-CNCR2>3.0.CO;2-D

      In this issue of Cancer, Ambrosch et al. discuss a proposal for regrouping the TNM elements of oropharyngeal carcinoma, thereby raising the issue of modifying the current staging criteria of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC). In response, this editorial discusses the question of whether there are currently sufficient data to warrant such modifications.

      See also pages 1613-20.

  3. Original Articles

    1. Top of page
    2. Cancer—50 Years Later
    3. Editorials
    4. Original Articles
    5. Correspondence
    6. Errata
    1. Anatomic Site

      You have free access to this content
      Clinical staging of oropharyngeal carcinoma : A critical evaluation of a new stage grouping proposal (pages 1613–1620)

      Petra Ambrosch, Martina Kron and Lutz S. Freudenberg

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1613::AID-CNCR3>3.0.CO;2-B

      • original image
      • original image
      • original image
      • original image

      The current International Union Against Cancer/American Joint Committee on Cancer stage grouping system for oropharyngeal carcinoma was compared with the revised staging system proposed by Hart et al. (1995) on behalf of the Dutch Head and Neck Oncology Cooperative Group. In the patient population studied, the revised staging system showed a more balanced distribution of patients and a better prognostic discrimination for overall survival.

      See also pages 1611-2.

    2. You have free access to this content
      Phenotype 2 of deoxyribonuclease I may be Used as a risk factor for gastric carcinoma (pages 1621–1625)

      Souichi Tsutsumi, Takayuki Asao, Yukio Nagamachi, Tamiko Nakajima, Toshihiro Yasuda and Koichiro Kishi

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1621::AID-CNCR4>3.0.CO;2-D

      The results of this study found that deoxyribonuclease I phenotype 2 may be used as a marker for gastric carcinoma.

    3. You have free access to this content
      High expression of thymidylate synthase is Associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy (pages 1626–1631)

      Kun-Huei Yeh, Chia-Tung Shun, Chi-Long Chen, Jaw-Town Lin, Wei-Jei Lee, Po-Huang Lee, Yao-Chang Chen and Ann-Lii Cheng

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1626::AID-CNCR5>3.0.CO;2-8

      • original imageoriginal imageoriginal imageoriginal image
      • original image
      • original image

      The expression of thymidylate synthase, as determined by immunohistochemistry, is a relatively reliable indicator of whether 5-fluorouracil should be used in the treatment of patients with gastric carcinoma.

    4. You have free access to this content
      A cost-effectiveness analysis of colorectal screening for hereditary nonpolyposis colorectal carcinoma gene carriers (pages 1632–1637)

      Hans F. A. Vasen, Marjolein van Ballegooijen, Eric Buskens, Jan K. Kleibeuker, Babs G. Taal, Gerrit Griffioen, Fokko M. Nagengast, Fred H. Menko and P. Meera Khan

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1632::AID-CNCR6>3.0.CO;2-C

      • original image

      Colorectal surveillance of hereditary nonpolyposis colorectal carcinoma gene carriers is effective and considerably less costly than no colorectal surveillance; therefore, it deserves to be supported by governmental agencies and health insurance organizations.

    5. You have free access to this content
      Needle tract implantation of hepatocellular carcinoma after percutaneous ethanol injection (pages 1638–1642)

      Hiroshi Ishii, Shuichi Okada, Takuji Okusaka, Masayoshi Yoshimori, Hidekazu Nakasuka, Kazuaki Shimada, Susumu Yamasaki, Yukihiro Nakanishi and Michiie Sakamoto

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1638::AID-CNCR7>3.0.CO;2-6

      • original imageoriginal image

      Needle tract implantation of hepatocellular carcinoma after percutaneous ethanol injection is not unusual, especially when tumors are ≥ 2 cm in greatest dimension, enhanced in the early phase on dynamic computed tomography, and/or moderately differentiated on biopsied specimens.

    6. You have free access to this content
      The usefulness of determining des-γ-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma (pages 1643–1648)

      Yuhsaku Mita, Yutaka Aoyagi, Masahiko Yanagi, Takeshi Suda, Yasufumi Suzuki and Hitoshi Asakura

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1643::AID-CNCR8>3.0.CO;2-B

      • original image

      Determination of des-γ-carboxy prothrombin by sensitive enzyme immunoassay is useful in the early diagnosis of hepatocellular carcinoma (HCC), especially in patients who have small HCCs (less than 2 cm in greatest dimension), because a high specificity is maintained.

    7. You have free access to this content
      Pancreatic carcinoma : Correlation between E-cadherin and α-catenin expression status and liver metastasis (pages 1649–1656)

      Naoto Gunji, Tatsuya Oda, Takeshi Todoroki, Nobuo Kanazawa, Tohru Kawamoto, Kenji Yuzawa, Aldo Scarpa and Katashi Fukao

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1649::AID-CNCR9>3.0.CO;2-5

      • original imageoriginal imageoriginal imageoriginal image
      • original imageoriginal image
      • original imageoriginal image
      • original imageoriginal image
      • original image

      There is a greater tendency for liver metastasis from primary pancreatic carcinoma in cases in which the E-cadherin/catenin-mediated cell-cell adhesion system remains intact.

    8. You have free access to this content
      Clonal karyotypic abnormalities of the hereditary multiple exostoses chromosomal loci 8q24.1 (EXT1) and 11p11-12 (EXT2) in patients with sporadic and hereditary osteochondromas (pages 1657–1663)

      Julia A. Bridge, Mari Nelson, Charlotte Örndal, Paramjit Bhatia and James R. Neff

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1657::AID-CNCR10>3.0.CO;2-3

      • original image
      • original image
      • original image

      Genetic analysis of 34 osteochondromas from 26 patients with and without hereditary multiple exostoses (HME) revealed loss or rearrangement of two HME-associated loci: 8q24.1 (EXT1) and 11p11-12 (EXT2). These findings support the hypothesis that loss or mutation of EXT1 and EXT2, putative tumor suppressor genes, may be important in the pathogenesis of sporadic as well as hereditary osteochondromata and suggest that similar to hereditary lesions, sporadic osteochondromas also are genetically heterogeneic.

    9. You have free access to this content
      Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography : Results of a prospective study of 100 patients (pages 1664–1671)

      Daniela Rinne, Richard P. Baum, Gustav Hör and Roland Kaufmann

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1664::AID-CNCR11>3.0.CO;2-2

      • original image
      • original image
      • original image
      • original image
      • original image

      In melanoma staging, positron emission tomography shows higher sensitivity, specificity, and accuracy than conventional imaging.

    10. You have free access to this content
      The risk of subsequent primary carcinoma of the pancreas in patients with cutaneous malignant melanoma (pages 1672–1676)

      Maryjean Schenk, Richard K. Severson and Karen S. Pawlish

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1672::AID-CNCR12>3.0.CO;2-1

      An increased risk of carcinoma of the pancreas may be associated with malignant melanoma that is diagnosed in patients age < 50 years. Further research is needed to explore this potential association.

    11. You have free access to this content
      Interferon-α and chemohormonal therapy for patients with advanced melanoma : Final results of a Phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program (pages 1677–1681)

      James J. Stark, Robert O. Dillman, Richard Schulof, Michael C. Wiemann, Neil M. Barth, Pamela J. Honeycutt and Gamini Soori

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1677::AID-CNCR13>3.0.CO;2-1

      • original image

      The addition of a low dose of interferon-α during and after combination chemotherapy resulted in increased toxicity but no evidence of improvements in the response rate or survival.

    12. You have free access to this content
      Hot flashes in postmenopausal women treated for breast carcinoma : Prevalence, severity, correlates, management, and relation to quality of life (pages 1682–1691)

      Janet S. Carpenter, Michael A. Andrykowski, Matthew Cordova, Lauren Cunningham, Jamie Studts, Patrick McGrath, Daniel Kenady, David Sloan and Rita Munn

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1682::AID-CNCR14>3.0.CO;2-0

      Hot flashes are a significant problem for a majority of women after treatment for breast carcinoma.

    13. You have free access to this content
      A comparison of screening mammography results from programs for women of different socioeconomic status (pages 1692–1697)

      D. David Dershaw, Lisa Loring, Susan J. True, David C. Momrow, Laura Liberman and Elizabeth A. Morris

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1692::AID-CNCR15>3.0.CO;2-#

      Screening mammography programs can be as effective for women of lower socioeconomic status as for more affluent women, and they can be conducted with comparable efficiency. Considerable mortality reduction can be expected to result from these programs.

    14. You have free access to this content
      The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma (pages 1698–1703)

      Katsuyoshi Katase, Yuko Sugiyama, Katsuhiko Hasumi, Masataka Yoshimoto and Fujio Kasumi

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1698::AID-CNCR16>3.0.CO;2-#

      • original image

      Tamoxifen use does not appear to increase the incidence of subsequent endometrial carcinoma in patients with primary breast carcinoma.

    15. You have free access to this content
      Minimally invasive breast carcinoma staging using lymphatic mapping with radiolabeled dextran (pages 1704–1708)

      Regina Offodile, Carl Hoh, Sanford H. Barsky, Scott D. Nelson, Robert Elashoff, Frederick R. Eilber, James S. Economou and Mai Nguyen

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1704::AID-CNCR17>3.0.CO;2-8

      Resection of the sentinel lymph node(s) can be an accurate method for staging breast carcinoma.

    16. You have free access to this content
      Immunohistochemical detection of sex steroid receptors, cyclins, and cyclin-dependent kinases in the normal and neoplastic squamous epithelia of the uterine cervix (pages 1709–1719)

      Makoto Kanai, Tanri Shiozawa, Lu Xin, Toshio Nikaido and Shingo Fujii

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1709::AID-CNCR18>3.0.CO;2-8

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Results of immunostaining suggest that malignant transformation of the ectocervical squamous epithelium is associated with abnormal expression of steroid receptors, as well as with elevated expression of cell cycle-related molecules. In addition, different classes of cyclins appear to confer different growth activity to the squamous cell carcinoma of the uterine cervix.

    17. You have free access to this content
      CA 125 may not reflect disease status in patients with uterine serous carcinoma (pages 1720–1725)

      Fredric V. Price, Setsuko K. Chambers, Maria Luisa Carcangiu, Ernest I. Kohorn, Peter E. Schwartz and Joseph T. Chambers

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1720::AID-CNCR19>3.0.CO;2-6

      • original image
      • original image
      • original image
      • original image

      CA 125 has been advocated as a marker of subclinical endometrial carcinoma, but did not add to other information available at the time of surgical staging or during clinical surveillance in this group of high risk patients.

    18. You have free access to this content
      1H-magnetic resonance spectroscopy : A new technique to discriminate benign from malignant ovarian tumors (pages 1726–1730)

      Leon F. A. G. Massuger, Peter B. J. van Vierzen, Udo Engelke, Arend Heerschap and Ron Wevers

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1731::AID-CNCR20>3.0.CO;2-4

      • original image
      • original image

      1H-NMR spectroscopy of fluid from ovarian cysts can be used to differentiate benign from malignant ovarian cysts. This ultimately may lead to the noninvasive differential diagnosis of ovarian tumors by in vivo magnetic resonance spectroscopy.

    19. You have free access to this content
      Primary ovarian sarcoma : Analysis of prognostic variables and the role of surgical cytoreduction (pages 1731–1737)

      Anil K. Sood, Joel I. Sorosky, Mark S. Gelder, Richard E. Buller, Barrie Anderson, Edward J. Wilkinson, Jo A. Benda and Linda S. Morgan

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1738::AID-CNCR21>3.0.CO;2-4

      • original image
      • original image
      • original image
      • original image

      Optimal surgical cytoreduction and platinum-based chemotherapy improve outcome in patients with primary ovarian sarcoma.

    20. You have free access to this content
      Image analysis combined with visual cytology in the early detection of recurrent bladder carcinoma (pages 1738–1748)

      Allison M. Richman, Susan T. Mayne, James F. Jekel and Peter Albertsen

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1749::AID-CNCR22>3.0.CO;2-3

      • original image
      • original image
      • original image
      • original image
      • original image

      The combination of DNA image analysis and visual cytology may allow earlier detection of recurrent transitional cell carcinoma of the bladder.

    21. You have free access to this content
      The safety and efficacy of stereotactic biopsy for intracranial lesions (pages 1749–1755)

      Walter A. Hall

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1756::AID-CNCR23>3.0.CO;2-2

      • original image

      Stereotactic biopsy allows neurosurgeons to sample intrinsic lesions of the brain. In this series, the morbidity rate was found to be 0.7% with a mortality rate of 0.7% and a diagnostic yield of 96%. These results confirm the safety and efficacy of this surgical procedure for evaluating intracranial diseases.

    22. You have free access to this content
      Leptomeningeal metastases from solid tumors : A comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy (pages 1756–1763)

      Felix Bokstein, Alexander Lossos and Tali Siegal

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1764::AID-CNCR24>3.0.CO;2-1

      • original image
      • original image

      Exclusion of intra-cerebrospinal fluid chemotherapy from the treatment schedule of patients with leptomeningeal metastases of solid systemic tumors does not change the patients' survival or their overall response to treatment.

    23. You have free access to this content
      Acquired glanzmann's thrombasthenia associated with hodgkin's lymphoma : A case report and review of the literature (pages 1764–1768)

      Umekalsoom Malik, Janice P. Dutcher and Leslie Oleksowicz

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1769::AID-CNCR25>3.0.CO;2-1

      • original image

      A 53-year-old female with Hodgkin's lymphoma in remission presented with acquired Glanzmann's thrombasthenia associated with immunoglobulin M autoantibodies.

    24. General Topic

      Epidemiology
      You have free access to this content
      Trends in the survival of american indian, hispanic, and non-hispanic white cancer patients in new mexico and arizona, 1969-1994 (pages 1769–1783)

      Frank D. Gilliland, William C. Hunt and Charles R. Key

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1784::AID-CNCR26>3.0.CO;2-#

      • original image
      • original image
      • original image
      • original image

      Increased cancer control efforts were associated with earlier diagnosis, more patients receiving appropriate therapy, and improved survival for each ethnic group. However, the improvement in survival was greatest for non-Hispanic whites, and disparities in survival results for the different ethnic groups widened over the period of study.

    25. Palliative Care
      You have free access to this content
      Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes (pages 1784–1788)

      Susan K. Quella, Charles L. Loprinzi, Jeff A. Sloan, Nancy L. Vaught, Wanda L. DeKrey, Tammy Fischer, Gwen Finck, Nancy Pierson and Thomas Pisansky

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1789::AID-CNCR27>3.0.CO;2-#

      Low doses of megestrol acetate taken for 3 years or longer appear to be well tolerated and appear to control hot flashes in breast carcinoma survivors and men with prostate carcinoma.

    26. Pediatric Oncology
      You have free access to this content
      Development of unfavorable hepatoblastoma in children of very low birth weight : Results of a surgical and pathologic review (pages 1789–1796)

      Hitoshi Ikeda, Yoichi Hachitanda, Masako Tanimura, Kenichi Maruyama, Takenobu Koizumi and Yoshiaki Tsuchida

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1797::AID-CNCR28>3.0.CO;2-Z

      • original image

      Children of very low birth weight (< 1500 g), especially those born at 23-25 weeks of gestation, are at high risk of developing advanced hepatoblastomas. Complete resection of the tumor is difficult and patient outcome is worse than that for other patients with hepatoblastoma. A correlation between etiologic factors relevant to the patient's prematurity and the development of unfavorable hepatoblastoma is suggested.

  4. Correspondence

    1. Top of page
    2. Cancer—50 Years Later
    3. Editorials
    4. Original Articles
    5. Correspondence
    6. Errata
    1. You have free access to this content
    2. You have free access to this content
      Author reply (page 1799)

      Hiroyoshi Hiratsuka, Kenji Nakamori, Hajime Sunakawa and Gen-iku Kohama

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1799::AID-CNCR30>3.0.CO;2-Y

    3. You have free access to this content
      Ultra-late recurrence (15 years or longer) of cutaneous melanoma (pages 1799–1800)

      Helen Shaw, John Thompson and William McCarthy

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1800::AID-CNCR31>3.0.CO;2-6

    4. You have free access to this content
      Author reply (page 1800)

      Hensin Tsao and Arthur J. Sober

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1800::AID-CNCR32>3.0.CO;2-6

    5. You have free access to this content
      Fatal pulmonary toxicity resulting from treatment with gemcitabine (pages 1800–1801)

      Margaret A. Tempero and Randall Brand

      Article first published online: 31 OCT 2000 | DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1802::AID-CNCR33>3.0.CO;2-6

  5. Errata

    1. Top of page
    2. Cancer—50 Years Later
    3. Editorials
    4. Original Articles
    5. Correspondence
    6. Errata
    1. You have free access to this content
      Why is the prostate cancer death rate declining in the United States? (page 1802)

      CJ Mettlin and GP Murphy

      Article first published online: 31 OCT 2000 | DOI: 10.1002/1097-0142(19980501)82:9<1802::AID-CNCR34>3.0.CO;2-H

SEARCH

SEARCH BY CITATION